Introduction
============

Nasopharyngeal carcinoma (NPC) is a common malignancy that originates in the nasopharynx, and it exhibits a complex biology that is not fully understood. The incidence of NPC is rare in most populations, such as Europe and the United States, but it is a common cancer in southern China and Southeast Asia[@B1] and other populations, including the Middle East/North Africa and the Arctic. Genetics interact with the environment and contribute to the development of NPC because of the racial and ethnic geographical distribution of NPC worldwide[@B2].

A previous study used published data in endemic areas and demonstrated that concurrent chemoradiotherapy was an effective treatment for locally advanced NPC and improved overall survival[@B3]. A study also showed neoadjuvant chemotherapy and concurrent chemoradiotherapy can reduce distant failure as compared with concurrent chemoradiotherapy alone[@B4]. However, the percentage of patients with distant metastases is high in NPC, and patients with distant metastases exhibit poor prognosis[@B5]-[@B10]. Accordingly, NPC management should consider individual patient differences using recognized prognostic factors. It is important to identify biomarkers that are independently associated with rapidly progressive tumors to designate an appropriate treatment.

It is getting clear that cancer cells acquire alterations in the metabolism of carbohydrates, proteins, lipids and nucleic acids to meet the requirements for rapid proliferation[@B11]. Cancer cells need high amounts of nonessential and essential amino acids to fuel essential anabolic processes. Growing evidence suggests that amino acid metabolic pathways are also chemotherapeutic targets[@B12]. We used the published transcriptome of NPC to find genes involved in tumorigenesis[@B13] and demonstrated that phosphoserine aminotransferase 1 (*PSAT1*) was a prominently upregulated gene in the regulation of amino acid metabolism.

*PSAT1* was observed in the brains and livers of sheep[@B14]. *PSAT1* is involved in the second step of serine biosynthesis, and it converts 3-phosphohydroxypyruvate to L-phosphoserine[@B15]. *PSAT1* plays an important role in metabolic functions.*PSAT1*deficiency leads to seizures and acquired microcephaly[@B16], and overexpression of *PSAT1* correlates with cancer development[@B17]. However, information on the functions of*PSAT1* in the regulation of cell proliferation and tumorigenesis and the association between*PSAT1* overexpression and clinical implications in patients with NPC are not clear. Our study evaluated the influence of *PAST1*expression on the clinical outcome of NPC patients.

Materials and methods
=====================

Analysis of published transcriptomic datasets
---------------------------------------------

We evaluated one public transcriptome containing expression profiling data of (GSE34574) which contains expression profiling data deposited in the NIH Gene Expression Omnibus database. The raw CEL files of Affymetrix HUMAN Genome U133 Plus 2.0 microarray platform were imported into Nexus Expression 3 software (BioDiscovery) to analyze all probe sets without pre-selection or filtering. Supervised comparative analyses and functional profiling were performed to identify significant differentially expressed genes, and special attention was paid to pathways involved in amino acid biosynthesis in Gene Ontology (GO:0008652). Genes with *P*≦0.01 and a log~2~-transformed expression fold change \>1 were selected for further analysis. To crossly validate the findings, we also analyze another transcriptome dataset (GSE12452) for the selection of candidate gene as already been described in our previous publication[@B18].

Patients and tumor specimens
----------------------------

The institutional review board approved the procurement of formalin-fixed NPC tissue for this study (IRB10501-006). In brief, a total of 124 formalin-fixed paraffin-embedded tissue samples from NPC patients were used for *PSAT1* immunohistochemical evaluations. These patients were regularly followed up by physicians after biopsy in the Chi-Mei Medical Center. Patients who were initially diagnosed with NPC without distant metastasis underwent tissue biopsy between January 1998 and December 2002. Two pathologists (C.F. Li and T.J Chen) classified tumors by histological type based on WHO classifications[@B19]. Tumor stage was adjusted according to the American Joint Committee on Cancer Tumor-Nodes-Metastasis (TNM) classification of malignant tumors[@B20].

Immunohistochemical staining and assessment of PSAT1
----------------------------------------------------

Formalin-fixed, paraffin-embedded tissue samples were cut into 4-μm-thick sections. Paraffin-embedded tissues were deparaffinized using xylene, rehydrated in ethanol, and heated in a microwave using methods described in our previous study[@B21]. Tissue samples were washed in Tris-buffered saline for 15 min, and slides were incubated with a primary monoclonal antibody against *PSAT1* (1:100; Abcam).

Treatment and follow-up
-----------------------

All 124 NPC patients received a complete course of 3-dimensional radiotherapy (3DRT) in a constant protocol and were regularly followed-up until death or loss. The mean follow-up duration was 3 years. Patients with stage II-IV disease received concurrent cisplatin-based chemotherapy in addition to radiotherapy.

Statistical analysis
--------------------

The SPSS 14 software package was used to perform statistical data analyses. Chi-square or Fisher\'s exact test analyzed the relationship between*PSAT1* immunohistochemical expression and various clinicopathological parameters. The endpoints analyzed were local recurrence-free survival (LRFS), distant metastasis-free survival (DMFS), disease-specific survival (DSS), and overall survival (OS) which were calculated from the starting date of radiotherapy to the date of an event. Patients lost to follow-up were censored on the latest follow-up date. Multivariate analysis was performed using the Cox proportional hazards model. We also performed Kaplan-Meier analysis to compare the survival curves in NPC patients with different groups. The log-rank test was used to investigate differences in survival times between two groups. A *P*-value \<0.05 was considered statistically significant.

Results
=======

*PSAT1*was the most significantly upregulated gene associated with amino acid biosynthetic pathway in NPC
---------------------------------------------------------------------------------------------------------

Table [1](#T1){ref-type="table"} provides a summary of 8 significant differentially expressed genes associated with amino acid biosynthesis in the transcriptome of nasopharyngeal carcinomas (GSE34574). Of these, *ASNS*, *PSPH*, and *PSAT1* exhibited upregulated mRNA expression and *PSAT1* demonstrated the most significant upregulation (Logs ratio=4.2088, *P*\<0.0001, Fig. [1](#F1){ref-type="fig"}). Interestingly, we also confirmed *PSAT1* as the most significantly upregulated gene in an independent GEO dataset (GSE12452) which discloses *PSAT1* upregulaiton is most associated with the development of NPC (tumor versus non-tumor, log2 ratio=2.0392, *P*\<0.0001) in those associated with amino acid biosynthesis. Accordingly, we further evaluated the clinicopathological significance of *PSAT1* expression by immunohistochemistry.

Clinicopathological features of our NPC cohort
----------------------------------------------

Table [2](#T2){ref-type="table"} shows the associations between *PAST1* expression and important clinicopathological variables. The 124 cases of NPC consisted of 5 keratinizing squamous cell carcinomas, 54 non-keratinizing differentiated carcinomas, and 65 undifferentiated carcinomas. There were 95 males and 29 females, and 26 cases were older than 60 years of age. Thirty-eight cases were classified as stages I and II, and 85 cases were classified as stages III and IV. The mean follow-up period was 3 years, and the median duration to tumor-associated mortality was 2 years. The median durations to distal metastasis and local recurrence were 10 and 16 months, respectively.

Immunohistochemical expression of *PSAT1* and associations with clinicopathological features and treatment outcomes
-------------------------------------------------------------------------------------------------------------------

Low *PAST1* expression was significantly associated with T1-T2 classification (*P*=0.024) and stages I-II classification (*P*=0.019), but it was not related to histological grade. Of all important clinicopathological paraneters, T3-4 status, N2-3 status and AJCC III-IV stages, and high *PAST1* expression were all significantly predictive of worse outcomes for the three survival endpoints analyzed in univariate analyses (Table [3](#T3){ref-type="table"}, Fig. [3](#F3){ref-type="fig"}). AJCC III-IV stages remained prognostically independent for DSS (*P*=0.041, hazard ratio \[HR\]= 2.072), LRFS (*P*=0.028, HR= 2.935), and OS (*P*= 0.036, HR= 2.108) in multivariate comparisons, but it lost statistical significance for DMeFS (Table [4](#T4){ref-type="table"}). Moreover, high *PAST1* expression also predictive a more aggressive clinical course, with significantly shorter DSS (HR= 2.856, 95% CI 1.599 to 5.101), DMeFS (HR= 3.305, 95% CI 1.720 to 6.347), LRFS (HR= 2.834, 95% CI 1.376 to 5.835), and OS (HR= 2.935, 95% CI 1.646-5.234) in multivariate analyses.

Discussion
==========

*PSAT1* is an aminotransferase that plays an important role in linking catabolic pathways (glycolysis) and amino acid (serine) biosynthesis. *PSAT1* is responsible for the second step in serine synthesis, and it converts 3-phosphohydroxypyruvate to phosphoserine. Serine is an important carbon source for purine nucleotides, phosphatidylcholine, phosphatidylserine, and other cellular metabolites. Cancer cells use glucose and glutamine to support energy and anabolic metabolism[@B22],[@B23], and *PSAT1* is overexpressed in some cancer cells. Cancer cells use non-amino acid precursors to synthesize glycine and serine, which was first noted in lymphomas[@B24].

A previous study demonstrated that serine biosynthesis played an important role in bone metastatic breast cancer. Three enzymes, *PSAT1*, phosphoserine phosphatase (*PSPH*) and phosphoglycerate dehydrogenase (*PHGDH*), were responsible for the phosphorylated pathway of L-serine biosynthesis[@B25]. Jason et al. found that much of the glycolytic carbon in melanoma was redirected to serine and glycine metabolism via *PHGDH*. *PSAT1* expression was also observed in melanoma[@B26]. *PSAT*1 is weakly expressed in normal colon tissue but is overexpressed in colon cancer, and its expression is associated with disease progression[@B27]-[@B28]. Yoon et al. followed 78 patients with recurrent colon cancer during a median follow-up duration of 55.5 months and found that *PHGDH*, pyruvate dehydrogenase kinase 1, and *PSAT* expression was significantly higher in tumor cells than normal tissue. Univariate analysis for recurrence-free survival in colon tumor cells demonstrated that pyruvate dehydrogenase kinase 2 positivity was the only positive prognostic factor, but there was no significant difference in multivariate analysis[@B29].

The regulatory mechanism of *PSAT1* expression remains largely unknown. But it has been reported that MicroRNA (MiR)-340, playing a role in tumor suppression in esophageal squamous cell carcinoma, inhibits tumor proliferation via targeting of *PSAT1*, and *PSAT1*. In this manner, MiR-340 is involved in cancer cell proliferation and invasion in esophageal squamous cell carcinoma, suggesting a possible regulatory mechanism of *PSAT1* expression[@B30]. Few if any previous reports have disclosed the role of *PSAT1* in regulating cell proliferation. It is interesting that *PSAT1* is overexpressed in non-small cell lung cancer, and it is involved in tumor cell proliferation and cell cycle progression. *PSAT1* enhances G1 activity via modulation of cyclin D1 degradation and Rb-E2F pathway activity, suggesting its unique intracellular signaling axis[@B31].

Our study found that high *PSAT1* expression was a potent prognostic factor for DSS, DMeFS, LRFS and OS in NPC patients. The identification of biomarkers that independently correlate with tumor aggressiveness is important for the individualized management of high risk NPC. We confirmed increased hazard ratios of DSS, DMeFS, LRFS and OS in NPC patients with advanced stages (III-IV). A significant association between *PSAT1* expression, primary tumor size, nodal status and AJCC stage of NPC was observed. Therefore, we hypothesized that high *PSAT1* expression may represent NPC progression via an amino acid biosynthetic process.

*PSAT1* overexpression in colon and breast cancers correlates with advanced tumor stage, chemoresistance and poor prognosis to endocrine therapy[@B28]. A high expression level of *PSAT1* was associated with an advanced stage of NPC and poor prognosis compared to the NPC patients with low *PSAT1* expression in our study. The role of *PSAT1* in tumorigenesis and NPC development and progression and the use of *PSAT1* as a treatment target require further investigation.

In conclusion, *PSAT1* was overexpressed in the transcriptome of NPC, and NPC protein was identified in NPC tissue using immunohistochemistry. *PSAT1* was associated with advanced tumor stage, and it independently predicted a poor prognosis of NPC.

![Published transcriptomic datasets of NPC versus benign nasopharyngeal tissues samples were evaluated. *PSAT1* was an upregulated gene in the regulation of amino acid biosynthesis in the clustering analysis. Nasopharyngeal carcinoma (blue lines) and benign tissue (red lines) specimens are indicated at the top of the heatmap, and expression levels of upregulated and downregulated genes are expressed as a series of brightness of red and green colors, respectively. Unaltered mRNA expression is coded black.](jcav07p1088g001){#F1}

![Immunoexpression of *PSAT1* in benign nasopharyngeal epithelial tissue (A), low-stage (B), and high-stage (C) nasopharyngeal carcinomas, respectively. Immunohistochemically, *PSAT1* expression was barely detected in benign nasopharyngeal epithelial tissue and low-stage nasopharyngeal carcinoma, but it significantly upregulated in high-stage nasopharyngeal carcinoma](jcav07p1088g002){#F2}

![Log-rank test revealed that *PSAT1* overexpression was predictive of poor prognosis, including disease-specific survival, distant metastasis-free survival, local recurrence-free survival, and overall survival.](jcav07p1088g003){#F3}

###### 

Summary of differentially expressed genes associated with amino acid biosynthesis in the transcriptome of nasopharyngeal carcinomas (GSE34574)

  Probe          Comparison 1 Log ratio (NPC vs. Non-tumor tissue)   p-value    Gene Symbol   Gene Name                                                 Biological Process                                                                                                                                                                                                  Molecular Function
  -------------- --------------------------------------------------- ---------- ------------- --------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  223062_s\_at   4.2088                                              \<0.0001   ***PSAT1***   phosphoserine aminotransferase 1                          L-serine biosynthetic process, amino acid biosynthetic process, metabolic process, pyridoxine biosynthetic process                                                                                                  catalytic activity, phosphoserine transaminase activity, pyridoxal phosphate binding, transaminase activity, transferase activity
  205047_s\_at   3.4002                                              \<0.0001   *ASNS*        asparagine synthetase                                     amino acid biosynthetic process, asparagine biosynthetic process, glutamine metabolic process, metabolic process                                                                                                    asparagine synthase (glutamine-hydrolyzing) activity, ligase activity
  217956_s\_at   2.3727                                              0.0031     *ENOPH1*      enolase-phosphatase 1                                     amino acid biosynthetic process, metabolic process, methionine biosynthetic process                                                                                                                                 catalytic activity, hydrolase activity, magnesium ion binding, metal ion binding, phosphoglycolate phosphatase activity
  203774_at      2.0694                                              0.0004     *MTR*         5-methyltetrahydrofolate-homocysteine methyltransferase   amino acid biosynthetic process, central nervous system development, folic acid and derivative biosynthetic process, methionine biosynthetic process, nervous system development                                    cobalamin binding, cobalt ion binding, dihydropteroate synthase activity, homocysteine S-methyltransferase activity, metal ion binding, methionine synthase activity, methyltransferase activity, protein binding, transferase activity, zinc ion binding
  205048_s\_at   1.543                                               0.0047     *PSPH*        phosphoserine phosphatase                                 L-serine biosynthetic process, L-serine metabolic process, amino acid biosynthetic process, cell proliferation, metabolic process                                                                                   catalytic activity, hydrolase activity, magnesium ion binding, phosphoric monoester hydrolase activity, phosphoserine phosphatase activity, protein binding
  203576_at      -1.3603                                             0.0002     *BCAT2*       branched chain aminotransferase 2; mitochondrial          amino acid biosynthetic process, branched chain family amino acid biosynthetic process, branched chain family amino acid catabolic process, branched chain family amino acid metabolic process, metabolic process   branched-chain-amino-acid transaminase activity, catalytic activity, transaminase activity, transferase activity
  204608_at      -1.3908                                             0.0008     *ASL*         argininosuccinate lyase                                   amino acid biosynthetic process, arginine biosynthetic process, arginine biosynthetic process via ornithine, arginine catabolic process, urea cycle                                                                 argininosuccinate lyase activity, catalytic activity, lyase activity
  207076_s\_at   -3.6325                                             0.0001     *ASS1*        argininosuccinate synthetase 1                            amino acid biosynthetic process, arginine biosynthetic process, urea cycle                                                                                                                                          ATP binding, argininosuccinate synthase activity, ligase activity, nucleotide binding, protein binding

###### 

Associations between *PSAT1* expression with other important clinicopathological variables.

  Parameters               Category           *PSAT1* Exp.   p-value   
  ------------------------ ------------------ -------------- --------- -------------
  **Gender**               Male               47             48        0.832
                           Female             15             14        
  **Age (years)**          \<60 years         47             51        0.378
                           \>=60 years        15             11        
  **Primary tumor (T)**    T1-T2              46             34        **0.024\***
                           T3-T4              16             28        
  **Nodal status (N)**     N0-N1              31             25        0.279
                           N2-N3              31             37        
  **Stage**                I-II               25             13        **0.019\***
                           III-IV             37             49        
  **Histological grade**   Keratinizing       3              2         0.445
                           Non-keratinizing   30             24        
                           Undifferentiated   29             36        

###### 

Univariate log-rank analyses.

  Parameters               Category                        No. of case   DSS   DMeFS            LRFS   OS                                        
  ------------------------ ------------------------------- ------------- ----- ---------------- ------ ---------------- ---- -------------- ---- ----------------
  **Gender**               Male                            95            45    0.7870           38     0.6128           30   0.3240         46   0.7220
                           Female                          29            14                     11                      7                   14   
  **Age (years)**          \<60 years                      98            48    0.8600           42     0.3091           29   0.8206         49   0.8049
                           \>=60 years                     26            11                     7                       8                   11   
  **Primary tumor (T)**    T1-T2                           80            32    **0.0289\***     25     **0.0085\***     19   **0.0180\***   32   **0.0204\***
                           T3-T4                           44            27                     24                      18                  28   
  **Nodal status (N)**     N0-N1                           56            18    **0.0008\***     17     **0.0132\***     12   **0.0160\***   19   **0.0011\***
                           N2-N3                           68            41                     32                      25                  41   
  **Stage**                I-II                            38            10    **0.0020\***     9      **0.0072\***     5    **0.0026\***   10   **0.0020\***
                           III-IV                          86            49                     40                      32                  49   
  **Histological grade**   Keratinizing/Non-keratinizing   47            20    0.1980           17     0.2753           15   0.9521         20   0.1522
                           Undifferentiated                77            39                     32                      22                  40   
  **PAST1 Exp.**           Low Exp.                        60            17    **\<0.0001\***   13     **\<0.0001\***   11   **0.0002\***   17   **\<0.0001\***
                           High Exp.                       64            42                     36                      26                  42   

\*, Statistically significant; DSS, disease-specific survival; DMeFS, distal metastasis-free Survival; LRFS, local recurrence-free survival; OS, overall survival.

###### 

Multivariate survival analyses

  Parameter        Category    DSS         DMeFS             LRFS            OS                                                                                                                      
  ---------------- ----------- ----------- ----------------- --------------- ----------- ----------------- --------------- ----------- ----------------- ------------- ----------- ----------------- -------------
  **Stage**        I-II        **1**       \-                **0.041\***     1           \-                0.093           **1**       \-                **0.028\***   **1**       \-                **0.036\***
                   III-IV      **2.072**   **1.030-4.168**                   1.890       0.900-3.969                       **2.935**   **1.122-7.677**                 **2.108**   **1.048-4.238**   
  **PAST1 Exp.**   Low Exp.    **1**       \-                **\<0.001\***   **1**                         **\<0.001\***   **1**       **-**             **0.005\***   **1**       \-                **\<0.001**
                   High Exp.   **2.856**   **1.599-5.101**                   **3.305**   **1.720-6.347**                   **2.834**   **1.376-5.835**                 **2.935**   **1.646-5.234**   

\*, Statistically significant; DSS, disease-specific survival; DMeFS, distal metastasis-free Survival; LRFS, local recurrence-free survival; OS, overall survival
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